Abstract
The future of the pharmaceutical industry lies with biotechnology. Biological drugs are complicated, expensive products used to treat complex conditions but their contributions to public health are important. A number of biopharmaceuticals on the market have seen their patent protection expired which led to the development of biosimilars. Biosimilars are embedded in the field of biotechnology and their use in therapeutics raise some questions with respect to their safety because of complex production methodologies. This paper summarizes the French law regarding the safety and the development of such drugs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The International journal of risk & safety in medicine
Paper Title
Journal
Date
